25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

XBiotech Inc
Buy, Hold or Sell?

Let's analyze Xbiotech together

I guess you are interested in XBiotech Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of XBiotech Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about XBiotech Inc

I send you an email if I find something interesting about XBiotech Inc.

1. Quick Overview

1.1. Quick analysis of Xbiotech (30 sec.)










1.2. What can you expect buying and holding a share of Xbiotech? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
12.2%

What is your share worth?

Current worth
$6.46
Expected worth in 1 year
$5.39
How sure are you?
31.7%

+ What do you gain per year?

Total Gains per Share
$-1.06
Return On Investment
-14.4%

For what price can you sell your share?

Current Price per Share
$7.40
Expected price per share
$5.62 - $7.98
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Xbiotech (5 min.)




Live pricePrice per Share (EOD)
$7.40
Intrinsic Value Per Share
$-77.60 - $-10.04
Total Value Per Share
$-71.14 - $-3.58

2.2. Growth of Xbiotech (5 min.)




Is Xbiotech growing?

Current yearPrevious yearGrowGrow %
How rich?$196.7m$237.7m-$25.9m-12.2%

How much money is Xbiotech making?

Current yearPrevious yearGrowGrow %
Making money-$8.7m-$7.1m-$1.6m-18.8%
Net Profit Margin-139.7%-455.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Xbiotech (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#259 / 960

Most Revenue
#479 / 960

Most Profit
#519 / 960

Most Efficient
#506 / 960
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Xbiotech?

Welcome investor! Xbiotech's management wants to use your money to grow the business. In return you get a share of Xbiotech.

First you should know what it really means to hold a share of Xbiotech. And how you can make/lose money.

Speculation

The Price per Share of Xbiotech is $7.4. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Xbiotech.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Xbiotech, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.46. Based on the TTM, the Book Value Change Per Share is $-0.27 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Xbiotech.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.43-5.8%-0.29-3.9%-0.23-3.2%0.7610.3%0.233.1%
Usd Book Value Change Per Share-0.41-5.6%-0.27-3.6%-0.22-3.0%0.233.1%0.152.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.628.3%0.304.1%
Usd Total Gains Per Share-0.41-5.6%-0.27-3.6%-0.22-3.0%0.8511.4%0.456.1%
Usd Price Per Share5.14-5.35-4.13-9.91-8.94-
Price to Earnings Ratio-3.01--5.01--5.65--359.58--179.51-
Price-to-Total Gains Ratio-12.45--22.47--21.86-30.97-4.24-
Price to Book Ratio0.80-0.77-0.53-1.27-2.55-
Price-to-Total Gains Ratio-12.45--22.47--21.86-30.97-4.24-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.4
Number of shares135
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.62
Usd Book Value Change Per Share-0.270.23
Usd Total Gains Per Share-0.270.85
Gains per Quarter (135 shares)-35.85114.19
Gains per Year (135 shares)-143.41456.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-143-153332124447
20-287-296665249904
30-430-4399973731361
40-574-58213304981818
50-717-72516626222275
60-860-86819947462732
70-1004-101123278713189
80-1147-115426599953646
90-1291-1297299111194103
100-1434-1440332412444560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%1.040.00.02.4%1.043.00.02.3%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%5.015.00.025.0%10.030.01.024.4%11.030.03.025.0%
Dividend per Share0.00.04.00.0%2.00.010.016.7%5.00.015.025.0%5.00.036.012.2%5.00.039.011.4%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%8.012.00.040.0%13.027.01.031.7%14.027.03.031.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of XBiotech Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.413-0.266-36%-0.219-47%0.230-279%0.150-376%
Book Value Per Share--6.4576.955-7%7.806-17%9.157-29%5.509+17%
Current Ratio--11.12623.708-53%55.844-80%48.479-77%30.077-63%
Debt To Asset Ratio--0.0870.059+48%0.024+270%0.034+161%0.049+80%
Debt To Equity Ratio--0.0960.064+51%0.024+296%0.035+172%0.052+84%
Dividend Per Share----0%-0%0.616-100%0.300-100%
Eps---0.427-0.287-33%-0.233-45%0.762-156%0.233-283%
Free Cash Flow Per Share---0.394-0.201-49%-0.145-63%-0.089-77%-0.175-56%
Free Cash Flow To Equity Per Share---0.392-0.194-51%-0.070-82%-0.744+89%-0.341-13%
Gross Profit Margin--1.0331.043-1%1.000+3%1.009+2%1.004+3%
Intrinsic Value_10Y_max---10.036--------
Intrinsic Value_10Y_min---77.595--------
Intrinsic Value_1Y_max---0.711--------
Intrinsic Value_1Y_min---1.914--------
Intrinsic Value_3Y_max---2.360--------
Intrinsic Value_3Y_min---10.862--------
Intrinsic Value_5Y_max---4.281--------
Intrinsic Value_5Y_min---25.342--------
Market Cap225427680.000+31%156580848.000162901962.000-4%125813016.000+24%315743707.815-50%291545719.033-46%
Net Profit Margin----1.3970%-4.5530%-2.3520%-1.1480%
Operating Margin----1.8180%-9.1540%-3.7010%-1.8050%
Operating Ratio---1.855-100%8.252-100%4.075-100%1.988-100%
Pb Ratio1.146+31%0.7960.775+3%0.532+50%1.271-37%2.554-69%
Pe Ratio-4.333-44%-3.010-5.008+66%-5.646+88%-359.577+11847%-179.510+5864%
Price Per Share7.400+31%5.1405.348-4%4.130+24%9.909-48%8.938-42%
Price To Free Cash Flow Ratio-4.695-44%-3.261-10.198+213%-1.099-66%-5.664+74%-6.820+109%
Price To Total Gains Ratio-17.921-44%-12.448-22.473+81%-21.857+76%30.969-140%4.238-394%
Quick Ratio--11.06123.603-53%71.127-84%49.877-78%30.520-64%
Return On Assets---0.060-0.039-35%-0.029-52%0.016-474%-0.058-5%
Return On Equity---0.066-0.042-36%-0.030-55%0.018-458%-0.062-6%
Total Gains Per Share---0.413-0.266-36%-0.219-47%0.846-149%0.450-192%
Usd Book Value--196701000.000211871500.000-7%237794750.000-17%288495350.000-32%175679073.171+12%
Usd Book Value Change Per Share---0.413-0.266-36%-0.219-47%0.230-279%0.150-376%
Usd Book Value Per Share--6.4576.955-7%7.806-17%9.157-29%5.509+17%
Usd Dividend Per Share----0%-0%0.616-100%0.300-100%
Usd Eps---0.427-0.287-33%-0.233-45%0.762-156%0.233-283%
Usd Free Cash Flow---12003000.000-6132000.000-49%-4421250.000-63%-3290450.000-73%-5989000.000-50%
Usd Free Cash Flow Per Share---0.394-0.201-49%-0.145-63%-0.089-77%-0.175-56%
Usd Free Cash Flow To Equity Per Share---0.392-0.194-51%-0.070-82%-0.744+89%-0.341-13%
Usd Market Cap225427680.000+31%156580848.000162901962.000-4%125813016.000+24%315743707.815-50%291545719.033-46%
Usd Price Per Share7.400+31%5.1405.348-4%4.130+24%9.909-48%8.938-42%
Usd Profit---13006000.000-8751750.000-33%-7104750.000-45%28562200.000-146%9631585.366-235%
Usd Revenue---1310000.000-100%495000.000-100%3582050.000-100%1747341.463-100%
Usd Total Gains Per Share---0.413-0.266-36%-0.219-47%0.846-149%0.450-192%
 EOD+5 -3MRQTTM+3 -29YOY+7 -255Y+6 -2810Y+7 -27

3.3 Fundamental Score

Let's check the fundamental score of XBiotech Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.333
Price to Book Ratio (EOD)Between0-11.146
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than111.061
Current Ratio (MRQ)Greater than111.126
Debt to Asset Ratio (MRQ)Less than10.087
Debt to Equity Ratio (MRQ)Less than10.096
Return on Equity (MRQ)Greater than0.15-0.066
Return on Assets (MRQ)Greater than0.05-0.060
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of XBiotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.534
Ma 20Greater thanMa 506.900
Ma 50Greater thanMa 1006.716
Ma 100Greater thanMa 2006.731
OpenGreater thanClose7.670
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Fundamental data was last updated by Penke on 2024-09-13 12:19:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Xbiotech earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of XBiotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-139.7%+139.7%
TTM-139.7%YOY-455.3%+315.6%
TTM-139.7%5Y-235.2%+95.6%
5Y-235.2%10Y-114.8%-120.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--126.1%+126.1%
TTM-139.7%-194.5%+54.8%
YOY-455.3%-207.8%-247.5%
5Y-235.2%-373.2%+138.0%
10Y-114.8%-473.1%+358.3%
4.3.1.2. Return on Assets

Shows how efficient Xbiotech is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • -6.0% Return on Assets means that Xbiotech generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of XBiotech Inc:

  • The MRQ is -6.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.0%TTM-3.9%-2.1%
TTM-3.9%YOY-2.9%-1.0%
TTM-3.9%5Y1.6%-5.5%
5Y1.6%10Y-5.8%+7.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.0%-11.1%+5.1%
TTM-3.9%-11.9%+8.0%
YOY-2.9%-11.3%+8.4%
5Y1.6%-13.2%+14.8%
10Y-5.8%-14.9%+9.1%
4.3.1.3. Return on Equity

Shows how efficient Xbiotech is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • -6.6% Return on Equity means Xbiotech generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of XBiotech Inc:

  • The MRQ is -6.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.6%TTM-4.2%-2.4%
TTM-4.2%YOY-3.0%-1.2%
TTM-4.2%5Y1.8%-6.1%
5Y1.8%10Y-6.2%+8.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.6%-14.2%+7.6%
TTM-4.2%-16.0%+11.8%
YOY-3.0%-13.8%+10.8%
5Y1.8%-19.1%+20.9%
10Y-6.2%-19.8%+13.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of XBiotech Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Xbiotech is operating .

  • Measures how much profit Xbiotech makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of XBiotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-181.8%+181.8%
TTM-181.8%YOY-915.4%+733.6%
TTM-181.8%5Y-370.1%+188.3%
5Y-370.1%10Y-180.5%-189.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--279.4%+279.4%
TTM-181.8%-329.9%+148.1%
YOY-915.4%-230.4%-685.0%
5Y-370.1%-391.8%+21.7%
10Y-180.5%-499.6%+319.1%
4.3.2.2. Operating Ratio

Measures how efficient Xbiotech is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of XBiotech Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.855-1.855
TTM1.855YOY8.252-6.397
TTM1.8555Y4.075-2.220
5Y4.07510Y1.988+2.087
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.759-2.759
TTM1.8553.146-1.291
YOY8.2523.336+4.916
5Y4.0755.133-1.058
10Y1.9886.571-4.583
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of XBiotech Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Xbiotech is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 11.13 means the company has $11.13 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of XBiotech Inc:

  • The MRQ is 11.126. The company is very able to pay all its short-term debts. +2
  • The TTM is 23.708. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.126TTM23.708-12.582
TTM23.708YOY55.844-32.136
TTM23.7085Y48.479-24.771
5Y48.47910Y30.077+18.402
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.1263.806+7.320
TTM23.7084.010+19.698
YOY55.8444.719+51.125
5Y48.4795.980+42.499
10Y30.0776.318+23.759
4.4.3.2. Quick Ratio

Measures if Xbiotech is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • A Quick Ratio of 11.06 means the company can pay off $11.06 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of XBiotech Inc:

  • The MRQ is 11.061. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 23.603. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.061TTM23.603-12.542
TTM23.603YOY71.127-47.524
TTM23.6035Y49.877-26.274
5Y49.87710Y30.520+19.357
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.0613.346+7.715
TTM23.6033.567+20.036
YOY71.1274.698+66.429
5Y49.8775.910+43.967
10Y30.5206.500+24.020
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of XBiotech Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Xbiotech assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xbiotech to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09 means that Xbiotech assets are financed with 8.7% credit (debt) and the remaining percentage (100% - 8.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of XBiotech Inc:

  • The MRQ is 0.087. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.059. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.087TTM0.059+0.028
TTM0.059YOY0.024+0.035
TTM0.0595Y0.034+0.026
5Y0.03410Y0.049-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0870.342-0.255
TTM0.0590.344-0.285
YOY0.0240.309-0.285
5Y0.0340.365-0.331
10Y0.0490.384-0.335
4.5.4.2. Debt to Equity Ratio

Measures if Xbiotech is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xbiotech to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.6% means that company has $0.10 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of XBiotech Inc:

  • The MRQ is 0.096. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.064. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.096TTM0.064+0.032
TTM0.064YOY0.024+0.039
TTM0.0645Y0.035+0.028
5Y0.03510Y0.052-0.017
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0960.393-0.297
TTM0.0640.439-0.375
YOY0.0240.372-0.348
5Y0.0350.448-0.413
10Y0.0520.489-0.437
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Xbiotech generates.

  • Above 15 is considered overpriced but always compare Xbiotech to the Biotechnology industry mean.
  • A PE ratio of -3.01 means the investor is paying $-3.01 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of XBiotech Inc:

  • The EOD is -4.333. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.010. Based on the earnings, the company is expensive. -2
  • The TTM is -5.008. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.333MRQ-3.010-1.323
MRQ-3.010TTM-5.008+1.999
TTM-5.008YOY-5.646+0.638
TTM-5.0085Y-359.577+354.569
5Y-359.57710Y-179.510-180.068
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.333-2.310-2.023
MRQ-3.010-2.379-0.631
TTM-5.008-2.921-2.087
YOY-5.646-3.405-2.241
5Y-359.577-6.019-353.558
10Y-179.510-6.254-173.256
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of XBiotech Inc:

  • The EOD is -4.695. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.261. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.198. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.695MRQ-3.261-1.434
MRQ-3.261TTM-10.198+6.937
TTM-10.198YOY-1.099-9.099
TTM-10.1985Y-5.664-4.534
5Y-5.66410Y-6.820+1.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.695-2.954-1.741
MRQ-3.261-3.175-0.086
TTM-10.198-3.483-6.715
YOY-1.099-4.594+3.495
5Y-5.664-8.064+2.400
10Y-6.820-8.708+1.888
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Xbiotech is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.80 means the investor is paying $0.80 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of XBiotech Inc:

  • The EOD is 1.146. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.796. Based on the equity, the company is cheap. +2
  • The TTM is 0.775. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.146MRQ0.796+0.350
MRQ0.796TTM0.775+0.021
TTM0.775YOY0.532+0.243
TTM0.7755Y1.271-0.496
5Y1.27110Y2.554-1.283
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1461.886-0.740
MRQ0.7961.972-1.176
TTM0.7752.201-1.426
YOY0.5322.363-1.831
5Y1.2713.551-2.280
10Y2.5544.200-1.646
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of XBiotech Inc.

4.8.1. Institutions holding XBiotech Inc

Institutions are holding 15.08% of the shares of XBiotech Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30BlackRock Inc3.7230.00011134146827522269.8817
2024-06-30Vanguard Group Inc3.4040.0001103696914165415.8217
2024-06-30Geode Capital Management, LLC1.41220.0002430205235001120.3874
2024-06-30Millennium Management LLC1.18720.0009361661-565707-61.0014
2024-03-31Credit Suisse First Boston (CSFB)0.8150.001924827000
2024-06-30UBS Asset Mgmt Americas Inc0.8150.00042482702482700
2024-06-30State Street Corp0.66590.0001202843146317258.849
2024-06-30Bridgeway Capital Management, LLC0.50610.018615417848603.2548
2024-03-31Morgan Stanley - Brokerage Accounts0.38190.000111632758105.2571
2024-06-30Bank of New York Mellon Corp0.32270.00019831449863102.9143
2024-06-30Northern Trust Corp0.25740.00017840730184.0032
2024-06-30Connor Clark & Lunn Inv Mgmt Ltd0.25510.0017777233100.4004
2024-06-30American Century Companies Inc0.2510.000276460764600
2024-06-30Dimensional Fund Advisors, Inc.0.23790.00017247500
2024-06-30Empowered Funds, LLC0.2270.006269137-59417-46.2195
2024-06-30Charles Schwab Investment Management Inc0.17770.00015413943662416.7414
2024-06-30Nuveen Asset Management, LLC0.0817024879248790
2024-06-30T. Rowe Price Associates, Inc.0.0776023625602534.233
2024-06-30New York State Common Retirement Fund0.07120.000221700217000
2024-06-30FMR Inc0.070802157216068.0437
Total 14.94040.03114551300+1211833+26.6%

4.9.2. Funds holding XBiotech Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-07-31Vanguard Total Stock Mkt Idx Inv2.04630.000362335600
2024-08-30iShares Russell 2000 ETF1.33750.003740744725830.638
2024-07-31Vanguard Institutional Extnd Mkt Idx Tr0.96030.002129254700
2024-08-30iShares Russell 2000 Value ETF0.61160.0095186301-625-0.3344
2024-07-31Fidelity Extended Market Index0.37340.002111375819311.7268
2024-08-31Avantis US Small Cap Value ETF0.34990.005210658800
2024-07-31State St Russell Sm Cap® Indx SL Cl I0.29180.00668890000
2024-07-31Vanguard Russell 2000 ETF0.23830.00527258836975.3664
2024-06-30Bridgeway Ultra-Small Company0.21350.42916504100
2024-08-30EA Bridgeway Omni Small-Cap Value ETF0.20190.027561493920.1498
2024-07-31Schwab Small Cap Index0.14330.00524366200
2024-08-30iShares Micro-Cap ETF0.14170.03024316100
2024-07-31iShares Russell 2000 Small-Cap Idx Instl0.12110.00533689600
2024-06-30Russell 2000 Index Non-Lendable Fund E0.11550.003635196351960
2024-07-31Fidelity Total Market Index0.11420.000334778-46-0.1321
2024-06-30BlackRock Extended Equity Market K0.10610.001232331-31-0.0958
2024-06-30BlackRock Russell 2500™ Index F0.09580.001629178291780
2024-07-31Fidelity Series Total Market Index0.09160.00032790900
2024-06-30Nuveen Small Cap Blend Idx R60.08170.003824879248790
2024-06-30EQ/2000 Managed Volatility IB0.06860.003220885208850
Total 7.70410.5462346894+117739+5.0%

5.3. Insider Transactions

Insiders are holding 35.13% of the shares of XBiotech Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-10-14John SimardSELL2112512.9
2021-10-12John SimardSELL1800012.77
2021-10-07John SimardSELL3928612.45
2021-10-05John SimardSELL1421812.66
2021-10-01John SimardSELL1968413.23
2021-09-29John SimardSELL1639613.41
2021-09-27John SimardSELL2989014.81
2021-09-24John SimardSELL1141814.49
2021-09-22John SimardSELL1966915.14
2021-09-20John SimardSELL1347115.06
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets215,555
Total Liabilities18,854
Total Stockholder Equity196,701
 As reported
Total Liabilities 18,854
Total Stockholder Equity+ 196,701
Total Assets = 215,555

Assets

Total Assets215,555
Total Current Assets190,639
Long-term Assets24,916
Total Current Assets
Cash And Cash Equivalents 188,530
Net Receivables 993
Other Current Assets 1,116
Total Current Assets  (as reported)190,639
Total Current Assets  (calculated)190,639
+/-0
Long-term Assets
Property Plant Equipment 24,916
Long-term Assets Other 0
Long-term Assets  (as reported)24,916
Long-term Assets  (calculated)24,916
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities17,135
Long-term Liabilities1,719
Total Stockholder Equity196,701
Total Current Liabilities
Short-term Debt 10,000
Short Long Term Debt 10,000
Accounts payable 1,704
Other Current Liabilities 5,348
Total Current Liabilities  (as reported)17,135
Total Current Liabilities  (calculated)27,052
+/- 9,917
Long-term Liabilities
Long-term Liabilities  (as reported)1,719
Long-term Liabilities  (calculated)0
+/- 1,719
Total Stockholder Equity
Common Stock272,015
Retained Earnings -75,314
Total Stockholder Equity (as reported)196,701
Total Stockholder Equity (calculated)196,701
+/-0
Other
Capital Stock272,015
Cash and Short Term Investments 188,530
Common Stock Shares Outstanding 30,456
Current Deferred Revenue83
Liabilities and Stockholders Equity 215,555
Net Debt -178,530
Net Invested Capital 206,701
Net Working Capital 173,504
Property Plant and Equipment Gross 24,916
Short Long Term Debt Total 10,000



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-11-022017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
11,073
0
0
19,661
62,177
58,688
126,847
119,047
109,358
101,262
93,201
78,292
67,050
87,616
77,841
70,671
70,671
62,972
58,860
54,290
49,244
44,345
39,824
71,875
66,643
816,877
358,373
358,762
353,393
353,744
355,940
353,956
279,519
275,177
270,803
266,462
250,834
246,103
242,121
235,136
229,599
227,243
227,858
215,555
215,555227,858227,243229,599235,136242,121246,103250,834266,462270,803275,177279,519353,956355,940353,744353,393358,762358,373816,87766,64371,87539,82444,34549,24454,29058,86062,97270,67170,67177,84187,61667,05078,29293,201101,262109,358119,047126,84758,68862,17719,6610011,073
   > Total Current Assets 
7,693
0
0
15,871
58,064
53,765
120,353
107,587
93,041
79,839
66,328
48,841
36,930
57,085
47,301
40,289
40,289
33,332
29,749
25,766
21,306
17,016
12,982
45,599
40,911
716,263
257,896
258,389
251,685
325,875
327,899
324,863
250,237
246,870
242,980
238,764
223,427
219,843
216,284
209,512
204,402
201,718
203,056
190,639
190,639203,056201,718204,402209,512216,284219,843223,427238,764242,980246,870250,237324,863327,899325,875251,685258,389257,896716,26340,91145,59912,98217,01621,30625,76629,74933,33240,28940,28947,30157,08536,93048,84166,32879,83993,041107,587120,35353,76558,06415,871007,693
       Cash And Cash Equivalents 
7,244
0
0
15,497
57,329
52,236
117,382
105,680
91,051
78,225
64,798
46,793
34,324
54,632
45,949
38,977
38,977
31,768
28,416
24,849
20,849
15,823
12,019
44,921
40,338
714,594
241,540
229,703
238,431
237,366
239,879
315,258
238,877
236,983
231,821
225,793
160,568
157,306
152,484
143,391
202,191
200,023
201,039
188,530
188,530201,039200,023202,191143,391152,484157,306160,568225,793231,821236,983238,877315,258239,879237,366238,431229,703241,540714,59440,33844,92112,01915,82320,84924,84928,41631,76838,97738,97745,94954,63234,32446,79364,79878,22591,051105,680117,38252,23657,32915,497007,244
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75,000
0
75,058
0
0
0
0
0
0
0
59,532
60,172
60,178
61,380
0
0
0
0
000061,38060,17860,17259,532000000075,058075,00000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,474
25,654
12,172
10,687
5,036
8,134
10,441
8,953
10,527
12,426
2,706
1,764
2,919
3,794
1,332
935
945
993
9939459351,3323,7942,9191,7642,70612,42610,5278,95310,4418,1345,03610,68712,17225,65413,47400000000000000000000000000
       Other Current Assets 
449
0
0
374
735
1,529
2,971
1,907
1,990
1,614
1,530
2,048
2,606
2,453
1,352
1,312
1,564
1,564
1,333
917
457
1,193
963
678
573
1,669
2,882
3,032
1,082
77,822
82,984
1,471
919
9,887
632
545
62,859
601
703
947
879
760
1,072
1,116
1,1161,07276087994770360162,8595456329,8879191,47182,98477,8221,0823,0322,8821,6695736789631,1934579171,3331,5641,5641,3121,3522,4532,6062,0481,5301,6141,9901,9072,9711,52973537400449
   > Long-term Assets 
3,380
0
0
3,790
4,113
4,923
6,494
11,460
16,317
21,423
26,873
29,451
30,120
30,531
30,540
30,382
29,640
29,640
29,111
28,524
27,938
27,329
26,842
26,276
25,732
100,614
100,477
100,373
101,708
27,869
28,041
29,093
29,282
28,308
27,823
27,698
27,407
26,260
25,836
25,624
25,197
25,525
24,802
24,916
24,91624,80225,52525,19725,62425,83626,26027,40727,69827,82328,30829,28229,09328,04127,869101,708100,373100,477100,61425,73226,27626,84227,32927,93828,52429,11129,64029,64030,38230,54030,53130,12029,45126,87321,42316,31711,4606,4944,9234,1133,790003,380
       Property Plant Equipment 
3,380
0
0
3,790
4,113
4,923
6,494
11,460
16,317
21,423
26,873
29,451
30,120
30,531
30,540
30,382
30,382
29,640
29,111
28,524
27,938
27,329
26,842
26,276
25,732
25,171
25,034
24,882
26,207
27,336
27,508
28,451
28,640
28,308
27,823
27,276
26,635
26,260
25,836
25,624
25,197
24,897
24,802
24,916
24,91624,80224,89725,19725,62425,83626,26026,63527,27627,82328,30828,64028,45127,50827,33626,20724,88225,03425,17125,73226,27626,84227,32927,93828,52429,11129,64030,38230,38230,54030,53130,12029,45126,87321,42316,31711,4606,4944,9234,1133,790003,380
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75,443
75,443
75,491
75,501
533
533
642
642
-1
0
422
772
0
1
0
0
0
0
0
00000107724220-164264253353375,50175,49175,44375,4430000000000000000000000000
> Total Liabilities 
845
0
0
2,443
3,147
3,828
2,872
4,970
6,308
6,583
10,397
6,663
7,986
5,346
4,685
3,522
3,522
2,810
2,450
2,768
2,307
2,947
2,841
2,462
2,021
61,246
11,291
15,192
7,254
5,105
3,842
5,392
5,362
5,792
5,243
10,667
6,025
5,701
5,216
6,073
6,940
8,397
18,578
18,854
18,85418,5788,3976,9406,0735,2165,7016,02510,6675,2435,7925,3625,3923,8425,1057,25415,19211,29161,2462,0212,4622,8412,9472,3072,7682,4502,8103,5223,5224,6855,3467,9866,66310,3976,5836,3084,9702,8723,8283,1472,44300845
   > Total Current Liabilities 
845
0
0
2,443
3,147
3,826
2,865
4,958
6,291
6,563
10,376
6,641
7,963
5,323
4,663
3,502
3,502
2,792
2,434
2,756
2,300
2,944
2,841
2,462
2,021
60,190
10,235
14,136
6,198
3,984
2,721
3,891
3,861
3,453
2,891
8,235
3,578
4,066
3,618
4,450
5,294
6,100
16,884
17,135
17,13516,8846,1005,2944,4503,6184,0663,5788,2352,8913,4533,8613,8912,7213,9846,19814,13610,23560,1902,0212,4622,8412,9442,3002,7562,4342,7923,5023,5024,6635,3237,9636,64110,3766,5636,2914,9582,8653,8263,1472,44300845
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
49,361
1,715
2,565
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000
10,000
10,00010,000000000000000002,5651,71549,3610000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000
10,000
10,00010,000000000000000000000000000000000000000000000
       Accounts payable 
561
0
0
1,218
1,629
2,915
2,285
3,964
4,825
4,846
8,494
4,465
4,431
2,697
3,385
2,225
2,792
1,730
1,160
1,455
878
1,653
1,861
1,550
1,061
2,149
5,649
5,240
3,870
2,491
1,238
1,491
1,012
2,069
1,323
2,454
1,376
2,408
1,357
1,816
1,468
2,516
2,607
1,704
1,7042,6072,5161,4681,8161,3572,4081,3762,4541,3232,0691,0121,4911,2382,4913,8705,2405,6492,1491,0611,5501,8611,6538781,4551,1601,7302,7922,2253,3852,6974,4314,4658,4944,8464,8253,9642,2852,9151,6291,21800561
       Other Current Liabilities 
284
0
0
1,225
1,518
911
580
994
1,466
1,717
1,882
2,176
3,532
2,626
1,278
1,277
18
1,062
1,274
1,301
1,422
1,291
980
912
960
4,180
1,371
4,831
2,328
1,493
1,483
2,400
2,849
1,384
1,568
5,781
2,202
1,658
2,261
2,634
3,826
3,584
4,194
5,348
5,3484,1943,5843,8262,6342,2611,6582,2025,7811,5681,3842,8492,4001,4831,4932,3284,8311,3714,1809609129801,2911,4221,3011,2741,062181,2771,2782,6263,5322,1761,8821,7171,4669945809111,5181,22500284
   > Long-term Liabilities 
0
0
0
0
0
2
7
12
17
20
21
22
23
23
22
20
0
18
16
12
7
3
3
0
0
1,056
1,056
1,056
1,056
1,121
1,121
1,501
1,501
2,339
2,352
2,432
2,447
1,635
1,598
1,623
1,646
2,297
1,694
1,719
1,7191,6942,2971,6461,6231,5981,6352,4472,4322,3522,3391,5011,5011,1211,1211,0561,0561,0561,0560033712161802022232322212017127200000
       Other Liabilities 
0
0
0
0
0
2
7
12
17
20
21
22
23
23
22
20
0
18
16
12
7
3
0
0
0
1,056
1,056
1,056
1,056
1,121
1,121
1,501
1,501
2,339
2,352
2,432
2,447
1,635
0
1,623
0
0
0
0
00001,62301,6352,4472,4322,3522,3391,5011,5011,1211,1211,0561,0561,0561,0560003712161802022232322212017127200000
       Deferred Long Term Liability 
0
0
0
0
17
2
7
0
17
20
0
0
0
0
22
20
0
0
0
12
0
0
0
0
0
0
0
0
0
0
0
108
108
0
0
0
0
0
0
0
0
0
0
0
000000000001081080000000000012000202200002017072170000
> Total Stockholder Equity
10,228
0
0
17,218
59,030
54,860
123,975
114,077
103,050
94,679
82,804
71,629
59,064
82,270
73,156
67,149
60,162
60,162
56,410
51,522
46,937
41,398
36,983
69,413
64,622
755,631
347,082
343,570
346,139
348,639
352,098
348,564
274,157
269,385
265,560
255,795
244,809
240,402
236,905
229,063
222,659
218,846
209,280
196,701
196,701209,280218,846222,659229,063236,905240,402244,809255,795265,560269,385274,157348,564352,098348,639346,139343,570347,082755,63164,62269,41336,98341,39846,93751,52256,41060,16260,16267,14973,15682,27059,06471,62982,80494,679103,050114,077123,97554,86059,03017,2180010,228
   Common Stock
81,807
0
0
104,619
152,351
156,393
231,935
232,850
233,902
235,751
237,523
238,808
242,419
276,079
276,589
277,078
277,492
277,492
277,803
278,441
278,879
279,353
280,664
319,045
320,130
324,808
242,942
246,395
251,781
249,805
255,513
256,779
260,876
262,263
263,711
265,159
266,287
267,325
268,030
268,930
269,890
271,152
271,588
272,015
272,015271,588271,152269,890268,930268,030267,325266,287265,159263,711262,263260,876256,779255,513249,805251,781246,395242,942324,808320,130319,045280,664279,353278,879278,441277,803277,492277,492277,078276,589276,079242,419238,808237,523235,751233,902232,850231,935156,393152,351104,6190081,807
   Retained Earnings 
-71,444
0
0
-87,279
-93,168
-101,282
-108,026
-118,762
-130,651
-140,908
-154,529
-167,013
-183,412
-193,975
-203,107
-209,313
-209,313
-216,562
-220,631
-226,538
-231,589
-237,700
-243,564
-249,416
-255,566
430,929
104,156
97,312
94,786
97,568
95,000
89,882
11,618
5,151
-244
-11,888
-24,546
-27,749
-31,565
-40,307
-47,671
-52,306
-62,308
-75,314
-75,314-62,308-52,306-47,671-40,307-31,565-27,749-24,546-11,888-2445,15111,61889,88295,00097,56894,78697,312104,156430,929-255,566-249,416-243,564-237,700-231,589-226,538-220,631-216,562-209,313-209,313-203,107-193,975-183,412-167,013-154,529-140,908-130,651-118,762-108,026-101,282-93,168-87,27900-71,444
   Accumulated Other Comprehensive Income 
-135
0
0
-122
-153
-251
66
-11
-201
-164
-190
-166
57
166
-326
-616
-616
-768
-762
-381
-353
-255
-117
-216
58
-106
-16
-137
-428
1,266
1,585
1,903
1,663
1,971
2,093
2,524
3,068
826
440
440
440
0
0
0
0004404404408263,0682,5242,0931,9711,6631,9031,5851,266-428-137-16-10658-216-117-255-353-381-762-768-616-616-32616657-166-190-164-201-1166-251-153-12200-135
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue300
Cost of Revenue-1,744
Gross Profit-1,744-1,444
 
Operating Income (+$)
Gross Profit-1,744
Operating Expense-35,766
Operating Income-37,510-37,510
 
Operating Expense (+$)
Research Development32,848
Selling General Administrative4,662
Selling And Marketing Expenses1,744
Operating Expense35,76639,254
 
Net Interest Income (+$)
Interest Income10,290
Interest Expense-0
Other Finance Cost-0
Net Interest Income10,290
 
Pretax Income (+$)
Operating Income-37,510
Net Interest Income10,290
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-24,313-50,707
EBIT - interestExpense = -37,510
-24,313
-24,557
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-37,510-24,313
Earnings Before Interest and Taxes (EBITDA)-35,766
 
After tax Income (+$)
Income Before Tax-24,313
Tax Provision-921
Net Income From Continuing Ops-23,125-25,234
Net Income-24,557
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses37,510
Total Other Income/Expenses Net13,197-10,290
 

Technical Analysis of Xbiotech
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Xbiotech. The general trend of Xbiotech is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Xbiotech's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of XBiotech Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 7.5 < 7.55 < 7.98.

The bearish price targets are: 6.25 > 5.7 > 5.62.

Tweet this
XBiotech Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of XBiotech Inc. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

XBiotech Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of XBiotech Inc. The current macd is 0.19200579.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Xbiotech price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Xbiotech. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Xbiotech price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
XBiotech Inc Daily Moving Average Convergence/Divergence (MACD) ChartXBiotech Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of XBiotech Inc. The current adx is 19.99.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Xbiotech shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
XBiotech Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of XBiotech Inc. The current sar is 6.2836.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
XBiotech Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of XBiotech Inc. The current rsi is 56.53. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
XBiotech Inc Daily Relative Strength Index (RSI) ChartXBiotech Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of XBiotech Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Xbiotech price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
XBiotech Inc Daily Stochastic Oscillator ChartXBiotech Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of XBiotech Inc. The current cci is 104.61.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
XBiotech Inc Daily Commodity Channel Index (CCI) ChartXBiotech Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of XBiotech Inc. The current cmo is 15.58.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
XBiotech Inc Daily Chande Momentum Oscillator (CMO) ChartXBiotech Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of XBiotech Inc. The current willr is -33.52601156.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Xbiotech is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
XBiotech Inc Daily Williams %R ChartXBiotech Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of XBiotech Inc.

XBiotech Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of XBiotech Inc. The current atr is 0.55241246.

XBiotech Inc Daily Average True Range (ATR) ChartXBiotech Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of XBiotech Inc. The current obv is 4,678,521.

XBiotech Inc Daily On-Balance Volume (OBV) ChartXBiotech Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of XBiotech Inc. The current mfi is 44.08.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
XBiotech Inc Daily Money Flow Index (MFI) ChartXBiotech Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for XBiotech Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-05-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-05-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-31STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-03MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-06-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-06-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-07-02MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-07-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

XBiotech Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of XBiotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.534
Ma 20Greater thanMa 506.900
Ma 50Greater thanMa 1006.716
Ma 100Greater thanMa 2006.731
OpenGreater thanClose7.670
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Xbiotech with someone you think should read this too:
  • Are you bullish or bearish on Xbiotech? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Xbiotech? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about XBiotech Inc

I send you an email if I find something interesting about XBiotech Inc.


Comments

How you think about this?

Leave a comment

Stay informed about XBiotech Inc.

Receive notifications about XBiotech Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.